Charles Wu, Ph.D.

Charles Wu, Ph.D.

Former Chief Executive OfficeratGyre Therapeutics· In proxies 2022–2024

Pay in FY2024-86% from the year before · Gyre Therapeutics stock -52.9% the same year

Charles Wu, Ph.D. was paid $15.3K in FY2024 (Dec), down 86%. Gyre Therapeutics stock fell 52.9% that year.

Pay$100 in the stock at the end of FY21 → $542
Pay is from the Summary Compensation Table of each Gyre Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Gyre TherapeuticsPublic company · 4 yr
    • Former Chief Executive Officer2022 – Present · 4 yrStock in role +196%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?